Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...

Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), reducing the price target ...

Novo Nordisk (NYSE: NVO), and Vertex Pharmaceuticals (NASDAQ: VRTX) as magnificent stocks to buy and hold forever. (Eli Lilly): A forever stock you can put in your portfolio and not worry about is Eli ...

The FDA's approval of the non-addictive painkiller Journavx last week marked a milestone in the field of pain management. Why ...

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...

Vertex Pharmaceuticals (VRTX) shares soared 5.3% in the last trading session to close at $461.68. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

Orphans and children separated from their parents in Kadugli gather to eat boiled leaves at an IDP Camp within the Sudan People's Liberation Movement-North (SPLM-N) controlled area in Boram County ...